Skip to content
DataLookout
Menu

NCT07933016

QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Objective Response Rate (ORR) per RECIST v1.1
Timeframe: From first dose of study treatment to Week 104.

Secondary (2)

Progression-Free Survival (PFS) per RECIST v1.1
Overall Survival (OS)

Arms and interventions

Experimental: QL1706 Plus Lenvatinib and FOLFOX ChemotherapyExperimental

Participants receive QL1706 (iparomlimab and tuvonralimab, a PD-1/CTLA-4 antibody combination) 5 mg/kg IV over 30 minutes on Day 1 of each 21-day cycle; lenvatinib 8 mg/day (body weight \<60 kg) or 12 mg/day (≥60 kg) orally once daily; and FOLFOX every 3 weeks for up to 6 cycles: oxaliplatin 85 mg/m2 IV over 2 h, levoleucovorin calcium 200 mg/m2 IV, fluorouracil 400 mg/m2 IV bolus then 2400 mg/m2 IV infusion over 46 h, all on Day 1. When QL1706 and FOLFOX coincide, QL1706 is given first. QL1706 and lenvatinib continue until RECIST v1.1-confirmed progression, unacceptable toxicity, withdrawal of consent, or 2 years, whichever occurs first. For surgical conversion, lenvatinib is stopped 1 week before surgery; postoperative treatment follows pathological response.

Drugs: Intervention 1 - Drug QL1706 (Iparomlimab and Tuvonralimab) Intervention 2 - Drug Lenvatinib Intervention 3 - Drug FOLFOX Chemotherapy (Oxaliplatin, Fluorouracil, and Levoleucovorin Calcium)